Adjustable Continence Therapy (ACT®) balloons to treat female stress urinary incontinence: effectiveness, safety and risk factors of failure and complication.


Journal

International urogynecology journal
ISSN: 1433-3023
Titre abrégé: Int Urogynecol J
Pays: England
ID NLM: 101567041

Informations de publication

Date de publication:
04 2023
Historique:
received: 03 04 2022
accepted: 01 06 2022
medline: 28 3 2023
pubmed: 26 6 2022
entrez: 25 6 2022
Statut: ppublish

Résumé

To assess the effectiveness, safety and risk factors of failure and complications associated with Adjustable Continence Therapy (ACT®) balloons as a treatment for female stress urinary incontinence (SUI). In the present multicentric retrospective study, all women implanted with ACT® balloons between 2000 and 2018 were considered eligible. Effectiveness and safety were assessed at 1 year, and risk factors for failure and complications were sought. The effectiveness was categorized into three distinct groups: Success = maximum 1 pad/day and patient's impression of improvement using a numerical rating scale (NRS) ≥ 8/10; Improvement = decrease of daily pad use and NRS ≥ 5/10; Failure = increase or stability of daily pad use or NRS < 5/10. The intra- and postoperative surgical complications were collected. Over the study period, 281 women were included. Among them, 104 (37.0%), 94 (33.5%) and 83 (29.5%) were categorized as success, improvement, and failure, respectively. Intra-, early and late postoperative complications occurred in 13 (4.6%), 35 (12.5%) and 75 (26.7%) women, respectively. Most early surgical complications were minor according to the Dindo-Clavien classification. Of women that presented a late postoperative surgical complication, 64 (22.8%) underwent an explantation performed under local or general anesthesia without associated sequalae. The short-term effectiveness associated with ACT® balloons, their minimally invasive implantation and the frequent but easily manageable and sequelae-free complications suggest that they should be part of the therapeutic arsenal for female SUI.

Identifiants

pubmed: 35751672
doi: 10.1007/s00192-022-05275-6
pii: 10.1007/s00192-022-05275-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

877-883

Informations de copyright

© 2022. The International Urogynecological Association.

Références

Sussman RD, Syan R, Brucker BM. Guideline of guidelines: urinary incontinence in women. BJU Int. 2019. https://doi.org/10.1111/bju.14927 .
Lucas MG, Bosch RJL, Burkhard FC, et al. EAU guidelines on surgical treatment of urinary incontinence. Eur Urol. 2012;62:1118–29. https://doi.org/10.1016/j.eururo.2012.09.023 .
doi: 10.1016/j.eururo.2012.09.023 pubmed: 23040204
Chartier-kastler E, Costa P, Ben Naoum K, et al. Etude Française prospective multicentrique de l’utilisation des ballons ACT® pour le traitement de l’incontinence urinaire d’effort chez la femme. Progrès en Urologie. 2007;17:1372–7. https://doi.org/10.1016/S1166-7087(07)78580-9 .
doi: 10.1016/S1166-7087(07)78580-9 pubmed: 18271425
Kocjancic E, Crivellaro S, Smith JJ III, et al. Adjustable Continence Therapy for treatment of recurrent female urinary incontinence. J Endourol. 2008;22:1403–8. https://doi.org/10.1089/end.2008.0027 .
doi: 10.1089/end.2008.0027 pubmed: 18613782
Wachter J, Henning A, Roehlich M, et al. Adjustable continence therapy for female urinary incontinence: a minimally invasive option for difficult cases. Urol Int. 2008;81:160–6. https://doi.org/10.1159/000144054 .
doi: 10.1159/000144054 pubmed: 18758213
Aboseif SR, Franke EI, Nash SD, et al. The adjustable continence therapy system for recurrent female stress urinary incontinence: 1-year results of the North America Clinical Study Group. J Urol. 2009;181:2187–91. https://doi.org/10.1016/j.juro.2009.01.039 .
doi: 10.1016/j.juro.2009.01.039 pubmed: 19296967
Kocjancic E, Crivellaro S, Ranzoni S, et al. Adjustable continence therapy for severe intrinsic sphincter deficiency and recurrent female stress urinary incontinence: long-term experience. J Urol. 2010;184:1017–21. https://doi.org/10.1016/j.juro.2010.05.024 .
doi: 10.1016/j.juro.2010.05.024 pubmed: 20643464
Vayleux B, Luyckx F, Thélu S, et al. Adjustable Continence Therapy in women, middle term follow-up and a new technique for balloon positioning. Prog Urol. 2010;20:520–6. https://doi.org/10.1016/j.purol.2010.01.010 .
doi: 10.1016/j.purol.2010.01.010 pubmed: 20656275
Aboseif SR, Sassani P, Franke EI, et al. Treatment Of Moderate to severe female stress urinary incontinence with the adjustable continence therapy (ACT) device after failed surgical repair. World J Urol. 2011;29:249–53. https://doi.org/10.1007/s00345-010-0589-4 .
doi: 10.1007/s00345-010-0589-4 pubmed: 20959993
Biyani CS, Pecanka J, Rouprêt M, et al. Intraoperative Adverse Incident Classification (EAUiaiC) by the European Association of Urology ad hoc Complications Guidelines Panel. Eur Urol. 2020;77:601–10. https://doi.org/10.1016/j.eururo.2019.11.015 .
doi: 10.1016/j.eururo.2019.11.015 pubmed: 31787430
Dindo D, Demartines N, Clavien P-A. Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey. Annals Surg. 2004;240:205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae .
doi: 10.1097/01.sla.0000133083.54934.ae
Phé V, Nguyen K, Rouprêt M, et al. A systematic review of the treatment for female stress urinary incontinence by ACT® balloon placement (Uromedica, Irvine, CA, USA). World J Urol. 2014;32:495–505. https://doi.org/10.1007/s00345-013-1117-0 .
doi: 10.1007/s00345-013-1117-0 pubmed: 23783882
Gregori A, Romanò AL, Scieri F, et al. Transrectal ultrasound-guided implantation of Adjustable Continence Therapy (ProACT): surgical technique and clinical results after a mean follow-up of 2 years. Eur Urol. 2010;57:430–6. https://doi.org/10.1016/j.eururo.2009.11.031 .
doi: 10.1016/j.eururo.2009.11.031 pubmed: 19942340
Rouprêt M, Misraï V, Gosseine P-N, et al. Management Of Stress urinary incontinence following prostate surgery with minimally invasive adjustable continence balloon implants: functional results from a single center prospective study. J Urol. 2011;186:198–203. https://doi.org/10.1016/j.juro.2011.03.016 .
doi: 10.1016/j.juro.2011.03.016 pubmed: 21575974
Vayleux B, Rigaud J, Luyckx F, et al. Female urinary incontinence and artificial urinary sphincter: study of efficacy and risk factors for failure and complications. Eur Urol. 2011;59:1048–53. https://doi.org/10.1016/j.eururo.2011.03.006 .
doi: 10.1016/j.eururo.2011.03.006 pubmed: 21420781

Auteurs

Marie-Liesse de Guerry (ML)

University of Lille, Department of Urology, CHU Lille, F-59000, Lille, France.

Amélie Demeestere (A)

University of Lille, Department of Urology, CHU Lille, F-59000, Lille, France.

Christophe Bergot (C)

Department of Urology, CHU Nantes, Université de Nantes, Nantes, France.

Astrid de Hauteclocque (A)

Department of Urology, CHU Bordeaux, Université de Bordeaux, Bordeaux, France.

Juliette Hascoet (J)

Department of Urology, CHU Rennes, Université de Rennes, Rennes, France.

Anne-Sophie Bajeot (AS)

Department of Urology, CHU Rangueil, Université Paul Sabatier Toulouse III, Toulouse, France.

Camille Ternynck (C)

Department of Biostatistics, CHU Lille, 59000, Lille, France.

Xavier Gamé (X)

Department of Urology, CHU Rangueil, Université Paul Sabatier Toulouse III, Toulouse, France.

Benoît Peyronnet (B)

Department of Urology, CHU Rennes, Université de Rennes, Rennes, France.

Grégoire Capon (G)

Department of Urology, CHU Bordeaux, Université de Bordeaux, Bordeaux, France.

Marie-Aimée Perrouin-Verbe (MA)

Department of Urology, CHU Nantes, Université de Nantes, Nantes, France.

Xavier Biardeau (X)

University of Lille, Department of Urology, CHU Lille, F-59000, Lille, France. biardeau.xavier@gmail.com.
University of Lille, Inserm UMR-S1172 LilNCog, Lille Neuroscience and Cognition, CHU Lille, FHU Precise, 59000, Lille, France. biardeau.xavier@gmail.com.
University of Lille, Department of Urology, Lille University Hospital, 1 rue Polonovski, 59037, Lille Cedex, France. biardeau.xavier@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH